India's Biocon targets developed markets with biosimilars; EU ban to cost Indian industry $1.2B;

@FiercePharma: Harvard scientists link pesticides with bee losses. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Lupin lands its first US manufacturing site with $880M deal for GAVIS, 6-year-old NJ firm. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: UnitedHealth uses newfound scale to negotiate pay-for-performance deals. Article | Follow @CarlyHFierce

> India's Biocon said it expects to be introducing biosimilars into developed markets over the next three years as patents fall off. Story

> An EU ban on 700 generic drugs from India for which there were questions about how GVK Biosciences handled trials will cost the Indian industry an estimated $1.2 billion. Story

> Sun Pharmaceutical is expected to raise $1 billion with a bond sale after paying completing its $4 billion deal for Ranbaxy Laboratories. Report

> UK-based consumer health company Reckitt Benckiser today raised its full-year earnings forecast, saying it expects growth of 5%, helped in part by cold med Mucinex. Story

Medical Device News

@FierceMedDev: ICYMI: Oxford Performance Materials gets FDA nod for 3-D printed spinal implant. Report | Follow @FierceMedDev

@EmilyWFierce: ICYMI from FiercePharma: Shire CEO: We're prepared to wait for the right deal. Article | Follow @EmilyWFierce

> Varian signs $124M deal with U.K.'s NHS for ProBeam cancer therapy. News

> Sorin stock plummets as Italian feds seek to block its merger with Cyberonics. Story

> Docs dole out recs for reducing fetal ultrasound procedures in the U.S. More

Biotech News

@FierceBiotech: Allergan bags NMDA depression drugs in $560M-plus Naurex buyout. News | Follow @FierceBiotech

@JohnCFierce: The China stock landslide is back on. More from Reuters | Follow @JohnCFierce

@DamianFierce: I kinda forgot this hadn't already happened, tbh. Aegerion release/Article | Follow @DamianFierce

> Nymox soars after claims of a post-PhIII BPH turnaround. News

> Eli Lilly soldiers on in big PhIII evacetrapib study. Item

> Allergan joins the hunt for a 'transformational' biotech deal. Editor's corner

Animal Health News

> Animal health drives double-digit growth at Abaxis. Report

> Harvard scientists link pesticides with bee losses. Item

> H.J. Baker breaks ground on multimillion-dollar facility near KC animal health corridor. More

> USDA speeds development of bird flu vaccine as fears of revived virus mount. Article

> Aratana predicts full launch of two lymphoma drugs for dogs in late 2016. Story

Biotech IT News

> SynBio startup Ginkgo Bioworks lands $45M to fuel push into pharma. More

> PCORI board signs off on $142.5M investment to scale up health data network. Story

> BGI CEO steps down to escalate interest in artificial intelligence. Article

> Deep Genomics sets up shop to marry deep learning and genomics. Item

> Oxford Nanopore raises $109M ahead of key period for its sequencing technology. Report

Pharma Marketing News

> Sanofi draws a $14,600 line in the sand for Praluent payer fight. Report

> Spotlight-savvy Kim Kardashian adds Duchesnay med to her talking points. Story

> Will marketing make the difference in approval of Sprout's 'pink pill' for women? News

> J&J's Stelara may be under fire in psoriasis, but it's positioned to score elsewhere. More

> I'll prescribe it if you do: Prescribers susceptible to peer pressure, study finds. Report

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.